Lisenko K, Dingeldein G, Cremer M, Kriegsmann M, Ho AD, Rieger M, et al. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. BMC Cancer. 2017 May 22. 17 (1):359. [Medline]. [Full Text].
Miles RR, Mankey CC, Seiler CE 3rd, Smith LB, Teruya-Feldstein J, Hsi ED, et al. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. Hum Pathol. 2009 Dec. 40(12):1731-7. [Medline].
Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15. 106(4):1392-9. [Medline].
Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 1. 102(12):3871-9. [Medline].
Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006 Jan. 17(1):123-30. [Medline].
Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011 Mar. 22(3):664-70. [Medline].
Dubashi B, Cyriac S, Tenali SG. Clinicopathological analysis and outcome of primary mediastinal malignancies - A report of 91 cases from a single institute. Ann Thorac Med. 2009 Jul. 4(3):140-2. [Medline]. [Full Text].
van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001 Mar 15. 19(6):1855-64. [Medline].
Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011 Sep 8. 118(10):2659-69. [Medline].
Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005 Nov 1. 106(9):3183-90. [Medline].
Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer. 2007 Apr. 46(4):406-15. [Medline].
Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A. 1996 Jun 25. 93(13):6721-5. [Medline].
Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009 Sep 17. 114(12):2467-75. [Medline].
Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009 Jun 4. 459(7247):712-6. [Medline].
Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens. 2006 Jan. 67(1):1-9. [Medline].
Mottok A, Renné C, Seifert M, Oppermann E, Bechstein W, Hansmann ML. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood. 2009 Nov 12. 114(20):4503-6. [Medline].
Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, et al. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Rep. 2015 Nov 17. 13 (7):1418-31. [Medline].
Lazzarino M, Orlandi E, Paulli M, Sträter J, Klersy C, Gianelli U, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997 Apr. 15(4):1646-53. [Medline].
Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005 Nov. 29(11):1411-21. [Medline].
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. NCCN.org. Available at https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Version 4.2019 — June 18, 2019; Accessed: September 14, 2019.
Song HN, Kim SJ, Ko YH, Kim WS. Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. Acta Haematol. 2016. 136 (3):186-90. [Medline].
Sun W, Song K, Zervos M, Pass H, Cangiarella J, Bizekis C, et al. The diagnostic value of endobronchial ultrasound-guided needle biopsy in lung cancer and mediastinal adenopathy. Diagn Cytopathol. 2010 May. 38(5):337-42. [Medline].
Jackson MW, Rusthoven CG, Jones BL, Kamdar M, Rabinovitch R. Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis. Int J Radiat Oncol Biol Phys. 2015 Sep 25. [Medline].
Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009 Oct. 9(5):381-5. [Medline].
Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006 Jan. 17(1):123-30. [Medline].
Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999 Nov 15. 94(10):3289-93. [Medline].
Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013 Apr 11. 368(15):1408-16. [Medline].
Witzens-Harig M, Ho AD, Kuhnt E, Trneny M, Rieger M, Österborg A, et al. Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study. Blood (ASH Annual Meeting Abstracts). 2012. 120:Abstract 1612.
Jackson MW, Rusthoven CG, Jones BL, Kamdar M, Rabinovitch R. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. Am J Hematol. 2016 May. 91 (5):476-80. [Medline]. [Full Text].
Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol. 2001 Jan 15. 19(2):414-9. [Medline].
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000 Jun. 85(6):613-8. [Medline].
Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005 Aug 15. 106(4):1376-81. [Medline].
Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010 Apr 10. 28(11):1896-903. [Medline].
Savage KJ, Yenson PR, Shenkier T, Klasa R, Villa D, Goktepe O, et al. The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. Blood (ASH Annual Meeting Abstracts). 2012. 120:Abstract 303.
Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan. 16(1):63-9. [Medline].
[Guideline] Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep. 27 (suppl 5):v91-v102. [Medline]. [Full Text].
Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017 Jul 20. 130 (3):267-270. [Medline]. [Full Text].